[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581319":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":54,"collaborators":24,"id":57,"slug":24,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":24,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine group","EXPERIMENTAL","Patients will receive lidocaine (1.5 mg\u002Fkg loading then 1mg\u002Fkg\u002Fh infusion) just after induction of anesthesia induction and continued until the end of the operation.",[13],"Drug: Lidocaine",{"label":15,"type":10,"description":16,"interventionNames":17},"Dexmedetomidine group","Patients will receive 1 μg\u002Fkg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg\u002Fkg\u002Fh just after induction of anesthesia induction and continued until the end of the operation.",[18],"Drug: Dexmedetomidine",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Lidocaine",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"Dexmedetomidine",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Ahmed M Eldemerdash, MD","CONTACT","00201114959206","ahmedmonier@med.asu.edu.eg",[35],{"facility":5,"status":36,"city":37,"state":24,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Cairo","11591","Egypt",{"type":41,"coordinates":42},"Point",[43,44],31.24967,30.06263,{"lat":44,"lon":43},[47,49,52],{"name":48,"role":31,"phone":32,"phoneExt":24,"email":33},"Ahmed M Eldemerdash",{"name":50,"role":51,"phone":24,"phoneExt":24,"email":24},"Sarah A Afifi, MD","PRINCIPAL_INVESTIGATOR",{"name":53,"role":51,"phone":24,"phoneExt":24,"email":24},"Sondos Afifi, MD",{"type":51,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Ahmed Monier Ahmed Youssef Eldemerdash","Lecturer of Anesthesia, Intensive care, and pain management Faculty of Medicine Ain Shams University","100581319",false,"NCT06848764","Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Functional Endoscopic Sinus Surgery","A Randomized Double-Blind Trial Comparing Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Patients Undergoing Functional Endoscopic Sinus Surgery","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* American Society of Anesthesiologists (ASA) physical status I - II.\n* Scheduled for elective functional endoscopic sinus surgery.\n\nExclusion Criteria:\n\n* Diabetes mellitus.\n* Coagulation disorders.\n* Kidney and liver dysfunction.\n* Cerebrovascular disease.\n* Cardiovascular problems.\n* High blood pressure.\n* Asthma.\n* Chronic obstructive pulmonary disease (COPD).\n* End organ damage.\n* Psychosis.\n* Taking antipsychotic drugs.\n* Allergy to study drugs.\n* Substance abuse.\n* Taking beta blockers.\n* Heart rate of \\\u003C 55 beat\u002Fminute.","ALL","18 Years","65 Years",{"count":67,"type":68},40,"ESTIMATED","INTERVENTIONAL",[71],"NA","This work aims to compare lidocaine and dexmedetomidine infusions for intraoperative bleeding in patients undergoing functional endoscopic sinus surgery.",[22,26,74,75,76],"Infusion","Intraoperative Bleeding","Functional Endoscopic Sinus Surgery","2025-03-01",{"date":79,"type":80},"2025-03-05","ACTUAL",{"date":77,"type":80},{"date":83,"type":68},"2025-09-01",{"name":5,"class":6},1]